2,028 reports of this reaction
3.0% of all TESTOSTERONE reports
#7 most reported adverse reaction
PULMONARY EMBOLISM is the #7 most commonly reported adverse reaction for TESTOSTERONE, manufactured by ASCEND Therapeutics U.S., LLC. There are 2,028 FDA adverse event reports linking TESTOSTERONE to PULMONARY EMBOLISM. This represents approximately 3.0% of all 67,752 adverse event reports for this drug.
TESTOSTERONE has an overall safety score of 85 out of 100. Patients taking TESTOSTERONE who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for TESTOSTERONE, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for TESTOSTERONE:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 2,028 FDA reports for TESTOSTERONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 3.0% of all adverse event reports for TESTOSTERONE, making it a notable side effect.
If you experience pulmonary embolism while taking TESTOSTERONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.